Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Branten, A.
Right arrow Articles by Huysmans, F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Branten, A.
Right arrow Articles by Huysmans, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrology Dialysis Transplantation, Vol 13, Issue 2 421-424, Copyright © 1998 by Oxford University Press

ORIGINAL ARTICLES

Renal and systemic effects of atenolol and tertatolol in renal transplant recipients on cyclosporine A

A Branten, L Hilbrands, H van Hamersvelt, R Koene and F Huysmans
Department of Internal Medicine, Division of Nephrology, University Hospital Nijmegen, POB 9101, 6500 HB Nijmegen, The Netherlands; Corresponding author

Background. Hypertension and nephrotoxicity are well-known side-effects of cyclosporine A (CsA). CsA-induced vasoconstriction of the afferent glomerular arteriole probably plays a role in at least the nephrotoxicity. Frequently renal transplant recipients on CsA have to be treated with antihypertensive drugs and for this purpose also {beta}-blockers are used. Tertatolol is a new {beta}-blocker with specific vasodilatory properties, and thus might be particularly useful in CsA-treated transplant recipients. Methods. We studied the systemic and renal haemodynamic effects of atenolol and tertatolol in 12 hypertensive renal transplant recipients on cyclosporine A (CsA). In a cross-over way, all patients were treated with atenolol and tertatolol for 4 weeks each, separated by a wash-out period also of 4 weeks. At the end of each period, the mean arterial pressure (MAP), heart rate, glomerular filtration rate (GFR) and renal plasma flow (RPF) were measured. Results. The mean arterial pressure was lower (P<0.05) during atenolol (124±2 mm Hg) and tertatolol (125±2 mm Hg) treatment compared with wash out (132±4 mm Hg). Also the heart rate was lower (P<0.01) during atenolol and tertatolol (54±3 and 55±2 beats/min respectively) than in the wash-out period (65±3 beats/min). GFR and RPF were not changed by either {beta}-blocker. Conclusion. In CsA treated renal transplant recipients both atenolol and tertatolol effectively reduced blood pressure. In these patients we found no evidence of a specific vasodilatory effect of tertatolol. Both {beta}-blockers had no negative influence on renal function. Hence, these cardioprotective agents are an attractive and safe choice for the treatment of hypertension in such patients. Keywords: hypertension; transplantation; cyclosporine A; {beta}-blockers; renal haemodynamics
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.